Background/Introduction: Few data is currently available on neutropenia and agranulocytosis related to drug intake. Aim: We report here data on 203 patients with established idiosyncratic drug-induced agranulocytosis, followed up in a referral centre within a university hospital. Design: Data from 203 patients with idiosyncratic drug-induced agranulocytosis were retrospectively reviewed. Methods: All cases were extracted from a cohort study on agranulocytosis in the Strasbourg University Hospital (Strasbourg, France). Results: The mean age was 61.6 years old (range: 18-95), the gender ratio (F/M) was 1.3. Several comorbidities were present in 63.5%. The most frequent causative drugs were: antibiotics (49.3%), especially b-lactams and cotrimoxazole; antithyroid drugs (16.7%); neuroleptic and anti-epileptic agents (11.8%); antiviral agents (7.9%); and platelet aggregation inhibitors as ticlopidine and acid acetylsalicylic (6.9%). The main primary clinical manifestations during hospitalization included: isolated fever (26.3%); septicaemia (13.9%); documented pneumonia (13.4%); sore throat and acute tonsillitis (9.3%); and septic shock (6.7%). The mean neutrophil count at nadir was 0.148 Â 109/L (range: 0-0.48). All febrile patients were treated with broad-spectrum antibiotics and 107 (52.7%) with hematopoietic growth factors. The mean duration of haematological recovery (neutrophil count !1.5 Â 109/L) was 7.8 (range: 2-20). This mean duration was reduced to 2.1 days (range: 2-16) (p¼0.057) with hematopoietic growth factors. Outcome was favourable in 91.6% of patients; seventeen died. Thirty-seven patients (18.2%) required intensive care. Discussion/Conclusion: The present study demonstrated that idiosyncratic drug-induced agranulocytosis is a relative rare events; that antibiotics, antithyroid, neuroleptic and anti-epileptic agents, and platelet aggregation inhibitors are the main incriminated drug classes; that agranulocytosis typically serious, with at least 50% exhibiting severe sepsis and a mortality rate <10%; and that modern management of such disorder may reduce the infection-related mortality.
Introduction
Idiosyncratic drug-induced agranulocytosis (IDIA) or acute severe neutropenia is historically characterized by neutrophil count 0.5 Â 10 9 /L, impaired health and severe mucositis. 1 IDIA is a relatively rare disorder, has an annual incidence of 2-15 cases per million. 2 Whilst all drugs can be considered cause of IDIA, cotrimoxazole, antithyroid drugs, ticlopidine and clozapine are currently the typical causes cited. 3 Although patients experiencing IDIA may initially be asymptomatic, the neutropenia often translates into the onset of severe sepsis depending on its severity and depth. 3, 4 With appropriate management, the mortality rate of IDIA agranulocytosis is currently estimated at 5-10%. 2, 3 Data on severe neutropenia or IDIA are currently scarce in the literature. 5 In the present paper, we report data on 203 patients with established IDIA, followed up in a referral centre within a university hospital.
Materials and methods

Patients selection
All IDIA cases reported in patients hospitalized in the Strasbourg University Hospitals (a tertiary referral centre) since the 1980s were identified and included in a register (partial data published in 6, 7 ). Patients were recruited from the Internal Medicine, OncoHaematology, Geriatric Medicine, Rheumatology, and Digestive Surgery departments.
Inclusion criteria
The inclusion and exclusion criteria have been listed in Table 1 . All the cases fulfilled the international criteria of IDIA. 2, 8 All the cases also response to the criteria: "Vraisemblable" (likely causative), "Très vraisemblable" (very likely causative) of the French method for causality assessment of adverse drug reactions. 9 All IDIA cases were reported to the Regional Pharmacovigilance Centre of Alsace, France.
Collected data and method
The first objective of the current study is to well-describe the clinical picture and outcome of patients with established IDIA. The second objective is to describe the changing epidemiology of IDIA over time, including updating the profile of currently incriminated drugs. All data were obtained from patient files. For each case, the patient was seen by two members of the monitoring committee, with each of the following factors recorded (when available): age; gender; medical history and comorbidities (such as diabetes mellitus, cardio-or respiratory disorders, renal failure or systemic inflammatory disorders); clinical presentation; drugs administered (dose, route, start date and withdrawal date); absolute white blood cell, haemoglobin, and platelet counts; bone marrow analysis; clinical features; time to reach a neutrophil count exceeding 1.5 Â 10 9 /L (haematological recovery); use of haematopoietic growth factors (HGF), for example, granulocytecolony stimulating factor (G-CSF); number of days in hospital; final outcome; recourse to intensive care and mortality rate. A specific comparison of clinical pictures and outcome according to age of the patients: <75-years-old; !75-years-old and !85-years-old is realized.
Statistical analysis
Data were expressed as mean and standard deviation (SD) and analysed using the Mann-Whitney test and Student's t-test for paired data. The distribution of quantitative variables was assessed graphically and using the Shapiro-Wilk test. Comparison of quantitative variables between the two groups was performed using the non-parametric Mann-Whitney test. The qualitative variables were presented as numbers and percentages, analysed using Pearson's chi-squared or Fisher's exact test, depending on the number of patients. A univariate analysis was performed to find the factors associated with death and/or admission in intensive care unit. A P values <0.05 was considered statistically significant. Analyses were performed using the R software (Version 3.2.2).
Administrative data
All data were registered in the French national database of drug side-effects (Réseau des Centres Régionaux de Pharmacovigilence [CRP]). The data collected were subject to the French national data protection act (Commission Nationale Informatique et Liberté) (CNIL). This study received approval from the local ethics committee.
Results
From January 1984 to January 2014 (30 years), 203 patients with IDIA were registered. One patient presented two episodes of IDIA (with two different drugs: carbimazole and amoxicillin for the first patient, carbimazole and noramydopyrine for the second). The mean and median number of IDIA cases per year were 6.7 and 6 cases (range: 2-19) for a population base of over 1 million person, respectively. Figure 1 shows the number of cases per 5 years.
Patient base-line characteristics
All patients were Caucasian (n ¼ 203). Mean and median ages were 61.6 and 65 years (range: 18-95), respectively. One-hundred forty-two patients (70%) were younger than 
Causative drugs
A single drug was documented as 'causative' or 'likely causative' in all except 27 cases (86.7%), for which two to four drugs were suspected ( Table 2 ). The respective causative drugs were stopped during the first 48 h of admission in 123 patients (60.6%). The main drug families found to be causative were: antibiotics (n ¼ 100, 49.3%), especially b-lactams (n ¼ 52) and cotrimoxazole (n ¼ 19); antithyroid drugs (n ¼ 34, 16.7%); neuroleptic and anti-epileptic agents (n ¼ 24, 11.8%); antiviral agents (n ¼ 16, 7.9%) and platelet aggregation inhibitors (n ¼ 14, 6.9%), especially ticlopidine (n ¼ 10) (Figure 2 ). Since 1990 and 2000, no case of noramidopyrine-and ticlopidine-induced agranulocytosis was observed, respectively. Conversely, cases of IDIA associated with clozapine or antiviral agents were observed only since 2000 and 2005, respectively. All except one (n ¼ 15) and four fifth (n ¼ 52) of the cases of antiviral agents-and antibiotics-induced 
In 27 cases, > 2 drugs were suspected to be responsible for the occurrence of IDIA, b Dose < 300 mg/day. agranulocytosis were observed in hospitalized patients, respectively. In two-thirds of cases (n ¼ 135), patients were treated with at least five drugs, (mean: 5; range: 1-13). There was only one case of self-medication. The mean duration of the suspected drug intake was 18 days (range: 3-120). A quarter of the patients received the causative drug for at least 30 days.
Clinical manifestations
The main discovery circumstances were: decrease in neutrophil blood count on a routine numeration (n ¼ 106, 52.2%); isolated fever (n ¼ 74, 36.5%); severe oral mucositis (n ¼ 11, 5.4%); documented infections (n ¼ 8, 3.9%) and three cases (1.5%) of septic shock.
The main clinical presentations during hospitalization were (data available for n ¼ 194): isolated fever (unknown origin) (n ¼ 51, 26.3%); septicaemia (n ¼ 27, 13.9%); documented pneumonia (n ¼ 26, 13.4%); sore throat and acute tonsillitis (n ¼ 18, 9.3%) and septic shock (n ¼ 13, 6.7%). The remaining symptomatic patients presented documented infection (n ¼ 42, 21.7%), such as; cutaneous infection (n ¼ 12); deep abdominal or thoracic abscess (n ¼ 7); acute pyelonephritis (n ¼ 5); cholecytitis (n ¼ 3); colitis (n ¼ 3); infectious spondylitis (n ¼ 3); endocarditis (n ¼ 3); meningitides (n ¼ 2); infectious arthritis or osteonecrosis (n ¼ 2); parodiditis (n ¼ 1) and fever with deep venous thrombosis (n ¼ 1) ( 
Haematological data
At the neutrophil decrease nadir, the mean and median neutrophil counts were 0.148 and 0.08 Â 47-156). Twenty-three patients (11.3%) had thrombocytopenia (platelet count 100 Â 10 9 /L). The mean platelet count was 217 Â 10 9 /L (range: 7-694).
Bone-marrow analysis (data available for n ¼ 58) primarily detected myeloid hypocellularity with apparent cessation of myeloid precursor maturation (in the promyeloid stage) in 70.7% of cases (n ¼ 41).
Duration of hospitalization and outcome
All patients were treated, immediately and in first line, with broadspectrum parenteral antibiotherapy when exhibiting any sepsis features, often piperacilline (12 g/day) or cefotaxime (3 g/day) in association with netromycine (5 mg/kg/day) or amikacine (15 (Table 5) .
Outcome was favourable in 91.6% of subjects (n ¼ 186); seventeen patients (8.4%) died. Five patients died of uncontrolled septic shock due to Staphylococcus aureus and Pseudomonas aeruginosa. Eleven additional mortalities with several comorbidities were caused by acute cardiac failure (n ¼ 9), haemorrhage stroke (n ¼ 1) and massive pulmonary embolism (n ¼ 1) in all elderly frailty patients. In one patient, the cause of death was not determined. Twelve of these seventeen patients were treated with HGF.
Duration of haematological recovery and response to HGF
The mean and median durations of haematological recovery (from initial neutropenia documentation to neutrophil G-CSF (administered subcutaneously in a fixed dose of 300 mg/day) was given to 107 patients (52.7%), particularly those with neutrophil counts <0.1 Â 10 9 /L, severe clinical features of infection (e.g. collapse, septicaemia or extensive pneumonia) or unstabilized underlying disease. This HGF was administered for a mean duration of 4.9 days (range: 1-18). In these 107 patients, the mean duration of haematological recovery was reduced to 2.1 days (range: 2-16) (P ¼ 0.057). The mean duration of antibiotherapy and hospitalization were not impacted with the use of HGF: 22.3 (range: 7-120) and 30.9 (range: 5-200), respectively (all P > 0.4) (data not developed).
Comparison of patients according to age
A comparison of clinical pictures and outcome according to age of the patients: <75-years-old; !75-years-old and !85-years-old is presented in Table 6 . Our comparison of discovery circumstances and clinical manifestations during hospitalization revealed no statistical difference between <75 and !75-year-olds (all P > 0.3). Comparison of neutrophil counts at diagnosis revealed no statistical difference between the two groups (P ¼ 0.21). In contrast, comparison of neutrophil counts at nadir demonstrated a statistical difference between the groups, with deeper neutropenia observed in patients !75-years-old (P ¼ 0.04). Significantly, comparison of mortality between the <75 and !75-year-old groups revealed a statistical difference (P ¼ 0.023).
Discussion
To the best of our knowledge, this is one of the few studies of IDIA with patients from a single centre, with well-documented agranulocytosis and managed by the same procedure. Defining IDIA remains a controversial issue. • Number of death • Recourse to an intensive care unit
Only 2 of these deaths were related to infectious complications, b All these 4 deaths were related to comorbidities.
for IDIA, namely complete haematological recovery following removal of the causative drug, was fulfilled (except in the five who died of uncontrolled septic shock). As IDIA is a lifethreatening condition, no patient was re-challenged with the incriminated drug ('theoretical method of reference'). This work highlights the role of classical causative drugs: antibiotics (49.3%), especially b-lactams and cotrimoxazole; antithyroid drugs (16.7%); neuroleptic and anti-epileptic agents (11.8%) and platelet aggregation inhibitors (6.9%), especially ticlopidine (Figure 2) . We have previously reported some of these findings in an unselected elderly population over 90-years-old. 7 Our present data were in accordance with that published by Shapiro et al. 12 and van der Klauw et al. 13, 14 In our study antibiotics are the first offending drug class. Note, however, that it is in practice often very difficult to formally award neutropenia to a drug rather than the infection for which it was introduced. In our study, reported cases formally met the criteria accountability of literature. This study also highlights the role of emergence causative drugs as antiviral agents which represent 7.9% of our cases ( Table 2) . As described by Fattinger et al., we also found, especially in elderly patients, that poly-medication was a pre-disposing factor for IDIA, 15 yet self-medication was not. We observed that two-thirds of our patients received at least five drugs, whereas there was only one case of self-medication. Our data were consistent with previous studies in other populations showing a relatively increased incidence (Figure 1 ). In the early 1980s, the study of the IAAA has estimated the incidence of agranulocytosis in European countries to be 6.2 cases per million per year. 11 Over the years, several population-based studies have reported similar incidence, ranging from 2.4 to 15.4 cases per million per year. [12] [13] [14] Compared with these studies, we observed a relatively greater incidence with slightly increase over the years. In your opinion, this increase is due to better reporting of cases by doctors. In fact, our institutional procedure for the management of IDIA includes a systematic reporting of such adverse events. 2 A bias of awareness may perhaps also be involved. In fact, we conducted numerous educational activities around this theme these later years.
The clinical features of IDIA in our population did not differ from those of other series including patients of all ages. 3, 4 Comparison of clinical features according to age (<75-yearsold; !75-years-old and !85-years-old) appears to reveal no significant differences (Table 5 ). Severe infections (e.g. septicaemia, shock, extensive pneumonia or deep infection) were more frequent in ours, at least 50% of cases, probably due to the study design enrolling solely hospitalized patients (for details, see the section Patients and Methods). Over 25% of our patients presented features of severe sepsis, septic shock and/or SIRS and 18.2% required intensive care. Only 8.8% remained asymptomatic during hospitalization. Retrospectively, it is seemed that these patients may be perhaps being managed in home, especially if the patients are young and without comorbidity. 2 As discuss elsewhere, the severity of the clinical manifestations we described (Table 3) were also probably in relation with the severity of the neutropenia: mean and median neutrophil counts of our patients of 0.148 and 0.08 Â 10 9 /L (range: 0-0.48) at the neutrophil decrease nadir. To the best of our knowledge, this explains the difference with the other series in the literature. [11] [12] [13] [14] In our opinion, the appearance of atypical reported clinical manifestations in the present work (Table 3) is explained by the number of agranulocytosis associated with the antibiotic intake. Indeed, we have recorded as clinical manifestations the clinical manifestations for which they have been introduced, for example, endocarditis, meningitis, etc.
IDIA is a life-threatening disorder at any age, as well as in elderly subjects presenting with several comorbidities. It has a mortality rate of 5-20%. 2, 16 In a previous study involving 90 patients (all ages), we established a mortality rate of >5%. 7 In the present study, a mortality rate of 8.4% was found. Seventeen patients died, yet only five elderly patients died of sepsis in relation to agranulocytosis, namely uncontrolled septic shock due to S. aureus and P. aeruginosa. In our present study, 11 additional patients died of uncontrolled comorbidities. Note that our population here was relatively elderly (of the patients were older than 75 years) and that 63.5% of the patients presented underlying disease that were often not stabilized, especially cardiac and renal disorders. In the Julia et al. study, these latter criteria (old age [>65 years] and renal failure) were poor prognostic indicators as evidence of severe infections, in association with a neutrophil count <0.1 Â 10 9 /L. 4 In our centre, all patients received established care procedures (for details, see 2, 7 ). In our opinion, this may account for our good results (mortality <15%). In our experience, appropriate management of septic complications of IDIA, especially using broad-spectrum antibiotherapy and HGF, may improve the prognosis. 3, 17, 18 A faster haematological non-significantly recovery (neutrophil count >1.5 Â Â 10 9 /L) was observed in the HGF group: 2.1 days (P ¼ 0.057). Nevertheless, we observed no other improvements in these patients associated with HGF therapy, particularly relating to duration of antibiotherapy and hospitalization. These results do not go in the same direction as those we had previously reported, 2 but are consistent with those reported in recent larger studies of HGF therapy in adult IDIA patients. 2, 19, 20 Thus, for certain haematologist the usefulness of HGF remains controversy in case of IDIA. To support this view, the only available prospective randomized study (based on 24 patients with antithyroid-related IDIA) did not confirm the benefit of G-CSF. 21 Nevertheless, this negative result may be related to inappropriate G-CSF doses (100-200 mg/day).
2
Our study presented several limitations. Primarily, the data originated from a population covering a period of over 30 years. Thus, there may be heterogeneity concerning the causative drug and perhaps the management process. Moreover, all the patients were referrals. On the other hand, our study exhibits several strengths. It was one of the few studies to investigate IDIA with established and documented IDIA. In addition, this study was conducted in a single centre, with experienced physicians particularly accustomed to managing neutropenia and agranulocytosis.
Conclusion
In conclusion, our study demonstrated that IDIA is a relative rare events; that antibiotics (especially b-lactams and cotrimoxazole), antithyroid, neuroleptic and anti-epileptic agents, and platelet aggregation inhibitors (ticlopidine and acid acetylsalicylic) are the main incriminated drug classes; that IDIA is typically serious, with at least 50% exhibiting severe sepsis and a mortality rate <10%; and that modern management of IDIA may reduce the infection-related mortality.
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